Related Experiment Video
Updated: Oct 9, 2025
09:10
An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma
Published on: November 15, 2024
599
GammaTile for Gliomas: A Single-Center Case Series
Hailey C Budnick1, Angela M Richardson1, Kevin Shiue2
1Neurological Surgery, Indiana University Health, Indianapolis, USA.
Cureus
|December 20, 2021
Summary
GammaTile brachytherapy offers a safe option for recurrent brain tumors. Early outcomes in seven patients with recurrent gliomas show no implant-related complications and adequate radiation coverage.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Medical Devices
Background:
- GammaTile is an FDA-approved cesium 131 brachytherapy device for brain neoplasms.
- It is particularly useful for treating recurrent brain tumors.
- This study evaluates the early clinical experience with GammaTile in recurrent gliomas.
Observation:
- Seven patients with recurrent gliomas (including glioblastoma multiforme, gliosarcoma, and oligodendroglioma) were treated with GammaTile.
- Data collected included operative time, extent of resection, complications, length of stay, Glasgow Coma Scale scores, and dosimetry.
- Dosimetry indicated adequate radiation coverage in six out of seven patients.
Findings:
- Surgical parameters, including operation time and length of stay, were within expected ranges for tumor resection.
- No postoperative complications were attributed to the GammaTiles themselves.
- Six of seven patients achieved adequate radiation coverage, with one limited by proximity to organs at risk.
Implications:
- GammaTile brachytherapy appears to be a safe and effective treatment option for recurrent gliomas.
- This early experience suggests GammaTile can be easily integrated into surgical planning and execution.
- Further research is warranted to confirm long-term efficacy and expand indications.
